NOLA (NeuWave Observational Liver Ablation) Registry
Reason given: Change in Company Strategy
Key facts
- Where
- Charlottesville, Houston, Jacksonville, Loma Linda, Los Angeles, Madison, New York, Philadelphia, Sacramento, Sarasota, Seattle, and Sylmar, United StatesSee the 14 sites
Where in United States
- University of VirginiaCharlottesville, United StatesNo longer taking part
- MD Anderson Cancer CenterHouston, United StatesNo longer taking part
- Mayo ClinicJacksonville, United StatesNo longer taking part
- Loma Linda University Medical CenterLoma Linda, United StatesNo longer taking part
- Cedars-Sinai Medical CenterLos Angeles, United StatesNo longer taking part
- David Geffen School of Medicine at UCLALos Angeles, United StatesNo longer taking part
- University of Wisconsin at MadisonMadison, United StatesNo longer taking part
- Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesNo longer taking part
- Thomas Jefferson UniversityPhiladelphia, United StatesNo longer taking part
- Sutter Institute for Medical ResearchSacramento, United StatesNo longer taking part
- Sarasota Memorial HospitalSarasota, United StatesNo longer taking part
- University of Washington Medical CenterSeattle, United StatesNo longer taking part
- Olive View UCLASylmar, United StatesNo longer taking part
Trial details
- Who runs it
- Ethicon, Inc.
- Trial code
- NCT04107766
- Record updated
- 17 April 2026
- Original description
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.Read full original descriptionShow less
A Multicenter Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
Inclusion: Patients who underwent or are scheduled to undergo a microwave ablation of one or more liver lesions with the NEUWAVE Microwave Ablation System per the device's Instructions for Use (IFU); Patients with signed informed consent (or waiver approved by IRB/EC) who are willing to comply with the assessment schedule, and willing to have data included in the database; Patients greater than or equal to 22 years old at the time of informed consent (or waiver approved by IRB/EC).
Exclusion: Patient is currently participating, or planning to participate, in another NeuWave/Ethicon-funded clinical trial or registry studying microwave ablation in the liver. Note: roll-over patients from previous NeuWave trials are permitted; Patients with a life expectancy of less than 1 year, in the opinion of the treating physician; Use of microwave ablation purely as a transection tool, rather than focused liver lesion ablation.